| Journal | European journal of pain (London, England) |
| Study Type | Clinical Study |
| Population | Human participants |
FABP5 inhibition represents a novel non-opioid, non-NSAID mechanism for pain management that may offer therapeutic benefits without traditional analgesic side effects. This pathway’s connection to endocannabinoid signaling through CB1 receptors provides mechanistic insight into how cannabis compounds might achieve analgesic effects.
This systematic review analyzed preclinical evidence for FABP5 (fatty acid-binding protein 5) as a pain management target through January-August 2025. Studies demonstrated that both pharmacological FABP5 inhibition and genetic knockout produced analgesic effects across visceral, inflammatory, neuropathic, and joint pain models. The mechanism involves modulation of lipid-signaling receptors, particularly cannabinoid receptor type 1 (CB1), suggesting intersection with endocannabinoid pathways. Notable limitations include the exclusively preclinical nature of current evidence and identified research gaps in sex differences and chronic dosing protocols.
“While this mechanistic pathway is scientifically intriguing, I remain cautious about clinical translation until human studies demonstrate safety and efficacy. The connection to CB1 signaling does help explain some of cannabis medicine’s analgesic mechanisms, but we need clinical data before considering this a viable therapeutic target.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is FABP5 and how does it relate to pain management?
FABP5 (fatty acid-binding protein 5) is an intracellular lipid transporter that plays a key role in pain signaling pathways. Preclinical studies demonstrate that inhibiting FABP5 produces analgesic effects across multiple pain models including visceral, inflammatory, neuropathic, and joint pain through modulation of endocannabinoid signaling via CB1 receptors.
Could FABP5 inhibitors serve as alternatives to opioids for pain management?
FABP5 inhibitors show promise as non-opioid analgesics based on preclinical evidence demonstrating pain relief across various pain models. The research suggests these compounds could potentially offer a novel therapeutic approach that avoids the risks associated with opioid medications, though human clinical trials are still needed.
What types of pain conditions might benefit from FABP5 inhibition?
Preclinical studies show FABP5 inhibition is effective in visceral pain, inflammatory pain, neuropathic pain, and joint pain models. Both pharmacological inhibition and genetic knockout/knockdown of FABP5 have demonstrated analgesic effects, particularly in visceral and inflammatory pain conditions.
How does FABP5 inhibition work to reduce pain?
FABP5 inhibition mediates analgesia through various lipid-signaling receptors, particularly the cannabinoid receptor type 1 (CB1). By blocking FABP5, the normal transport and metabolism of endocannabinoids is altered, leading to enhanced endocannabinoid signaling and subsequent pain relief.
What are the current limitations of FABP5 research for clinical application?
The research is currently limited to preclinical studies, with identified gaps including insufficient data on sex differences and chronic dosing effects in visceral and inflammatory pain models. Further research is needed before FABP5 inhibitors can be evaluated in human clinical trials for pain management.
